Relevance of endoplasmic reticulum stress cell signaling in liver cold ischemia reperfusion injury by Folch-Puy, Emma et al.
 International Journal of 
Molecular Sciences
Review
Relevance of Endoplasmic Reticulum Stress Cell
Signaling in Liver Cold Ischemia Reperfusion Injury
Emma Folch-Puy 1, Arnau Panisello 1, Joan Oliva 2, Alexandre Lopez 3, Carlos Castro Benítez 3,
René Adam 3 and Joan Roselló-Catafau 1,*
1 Experimental Pathology Department, Instituto de Investigaciones Biomédicas de Barcelona, Spanish
Research Council (IIBB-CSIC), Rosselló 161, 08036-Barcelona, Catalonia, Spain; efpbam@iibb.csic.es (E.F.-P.);
arnau.panisello@iibb.csic.es (A.P.)
2 Department of Medicine, LaBioMed at Harbor UCLA Medical Center, Torrance, 90502 CA, USA;
joliva@labiomed.org
3 Centre Hépatobiliaire, AP-HP Hôpital Paul Brousse, Inserm U935, Université Paris-Sud, Villejuif, 75008 Paris,
France; alexandregl.lopez@gmail.com (A.L.); ccastrob@gmail.com (C.C.B.); rene.adam@pbr.aphp.fr (R.A.)
* Correspondence: joan.rosello@iibb.csic.es; Tel.: +34-9336-38333; Fax: +34-9336-38301
Academic Editor: Masato Matsuoka
Received: 24 April 2016; Accepted: 17 May 2016; Published: 25 May 2016
Abstract: The endoplasmic reticulum (ER) is involved in calcium homeostasis, protein folding and
lipid biosynthesis. Perturbations in its normal functions lead to a condition called endoplasmic
reticulum stress (ERS). This can be triggered by many physiopathological conditions such as alcoholic
steatohepatitis, insulin resistance or ischemia-reperfusion injury. The cell reacts to ERS by initiating
a defensive process known as the unfolded protein response (UPR), which comprises cellular
mechanisms for adaptation and the safeguarding of cell survival or, in cases of excessively severe
stress, for the initiation of the cell death program. Recent experimental data suggest the involvement
of ERS in ischemia/reperfusion injury (IRI) of the liver graft, which has been considered as one of
major problems influencing outcome after liver transplantation. The purpose of this review is to
summarize updated data on the molecular mechanisms of ERS/UPR and the consequences of this
pathology, focusing specifically on solid organ preservation and liver transplantation models. We
will also discuss the potential role of ERS, beyond the simple adaptive response and the regulation of
cell death, in the modification of cell functional properties and phenotypic changes.
Keywords: endoplasmic reticulum stress; unfolded protein response; liver ischemia reperfusion
injury; orthotopic liver transplantation; University Wisconsin (UW) solution; Institut Georges Lopez-1
(IGL-1) solution
1. Introduction
The endoplasmic reticulum (ER) is an important intracellular organelle mainly responsible for
the synthesis, folding and trafficking of a wide variety of proteins, including hormones, enzymes,
receptors, ion channels and transporters. Under normal situations, a homeostatic equilibrium exists
between the influx of unfolded peptides and the folding ability of the ER. However, when unfolded or
misfolded proteins are accumulated in the organelle, endoplasmic reticulum stress (ERS) occurs and a
specific adaptive response from mammalian cells is triggered to prevent this abnormal accumulation
of unfolded proteins. ERS activates intracellular signal transduction pathways which together are
known as the unfolded protein response (UPR) [1]. This response is characterized by three phases:
an adaptive phase, an alarm phase and finally, a phase of cell death activation. The adaptive phase
is characterized by the proteasome degradation of proteins and the subsequent overall inhibition of
protein transduction that leads to increases in the chaperone pool and protein enzymes such as X box
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binding protein 1 (XBP-1) and activating transcription factor 4 (ATF4) [2]. This process limits ERS by
reducing the load of misfolded proteins. The next step is the alarm phase, consisting of the induction
of an inflammatory process by activation of Nuclear Factor-κB and c-Jun N-terminal kinases pathways.
Ultimately, if these mechanisms are insufficient to relieve the load of misfolded protein, ERS activates
an immune response against cell stress and eventually promotes at last the cell death [3].
Ischemia/reperfusion injury (IRI) of the liver graft is considered as one of crucial problems
complicating post-transplant patient care and influences short- and long-term outcomes after liver
transplantation. Since surgical techniques of transplantation obligate cold preservation and warm
reperfusion of grafts, inevitable IRI occurs in every case of liver transplantation. The cellular damage
in the hypoxic organ (ischemia-cold preservation) is worsened following the restoration of the oxygen
supply after reperfusion [4]. Besides, it is known that hepatocytes are exceptionally active in synthesis
of protein and lipids for export. As the result of these activities, ultrastructural examination of these
cells reveals abundant quantities of both rough and smooth ER. Hence, one may consider that UPR/ERS
response contribute either in preventing or mediating pathological changes in liver diseases. In this
sense, there is increasing evidence that ER perturbations are novel subcellular effectors involved in the
cold IRI associated with liver transplantation [5]. Certainly, ischemia reperfusion insult stimulates an
overload of intracellular Ca2+ from the ER lumen which in turns modulates mitochondrial calcium and
hepatocyte vulnerability to apoptosis, followed by cytochrome c release and caspase activation [6,7].
Once ER homeostasis is exacerbated, new unfolded proteins are accumulated and UPR is activated.
This occurs during cold storage of the liver graft in preservation solutions; UPR/ERS alterations are
then increased after reperfusion, which are determinant for the graft outcome after transplantation.
2. Key Players in the Endoplasmic Reticulum Stress (ERS) Response
In mammals, when the protein component of the ER increases, the signaling pathways of the
UPR are mediated by three ER transmembrane proteins: activating transcription factor 6 (ATF6),
inositol-requiring enzyme 1 (IRE1), and the PKR-like ER kinase (PERK). Under unstressful situations,
the luminal domains of these sensor proteins are captured by ER intraluminal 78 kDa glucose-regulated
protein (GRP78), also known as immunoglobulin-binding protein (BiP) [8]. Either by glucose
deprivation, by the depletion of calcium stores or by the accumulation of misfolded proteins, the
binding of GRP78 with misfolded and unfolded proteins is increased in ERS conditions, causing its
dissociation from ATF6, IRE1 and PERK; this dissociation results in the release of these proximal ERS
sensors and activates the UPR [9].
We next briefly describe the three main mediators involved in the signaling pathway of the UPR:
IRE1, PERK, and ATF6.
2.1. Inositol-Requiring Enzyme 1 (IRE1)
IRE1 is the most highly conserved branch of the UPR among mammals. Its cytoplasmic
tail has two enzymatic activities: a serine/threonine kinase domain and an endoribonuclease
(RNase) domain [10]. Following the binding of misfolded proteins in the lumen, IRE1’s kinase
is activated and trans-phosphorylates multiple serine/threonine residues on the cytosolic tail [11].
This phosphorylation causes the splicing of XBP1 mRNA. Spliced X box binding protein 1 (XBP1s)
translocate to the nucleus to positively control the transcription of ER-resident chaperones, the genes
involved in lipogenesis, the ER-associated protein degradation (ERAD) mechanism and ER quality
control [12]. IRE1 signaling and XBP1 splicing are especially important in highly secretory cells where
the machinery for protein folding is incessantly engaged with a high amount of nascent proteins [13].
Therefore, this branch of control serves as a key adaptive mechanism to match ER folding capacity
with the demands of protein folding [14].
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2.2. PKR-Like ER Kinase (PERK)
PERK is a type I ER transmembrane protein with serine/threonine kinase activity in its C-terminal
cytosolic domain. Activation of PERK entails homo-dimerization and auto phosphorylation, leading to
the phosphorylation of elongation initiation factor 2α (eIF2α). This phosphorylation inactivates eIF2α
activity and consequently, decreases global protein translation [15]. This leads to the reduction of the
ER protein-folding load. As an exception, ATF4 is selectively upregulated when the amount of active
eIF2α is limited, and participates in the transcription of genes involved in amino acid metabolism,
protein folding and autophagy [16].
2.3. Activating Transcription Factor 6 (ATF6)
ATF6 is a leucine zipper protein-containing transcription factor and a type II ER transmembrane
protein. In the presence of misfolded proteins, ATF6 dissociates from GRP78, travels to the Golgi
apparatus and is cleaved by the Site-1 and Site-2 proteases [17]. As a result, an N-terminal cytosolic
domain of ATF6 (ATF6 (N)) translocate to the nucleus, induces the transcription of a number of UPR
target genes (ER chaperones, transcription factors, components of ERAD and ER biogenesis) and
increases its protein-folding capacity to promote cell survival [18].
Together, these proteins induce a cascade of cell signals that decrease the accumulation of
misfolded proteins in the ER by upregulating ER chaperones expression, by inhibiting protein entry
into the ER and by exacerbating the retrograde export of proteins from the ER to the cytosol for
ubiquitination and degradation by the ubiquitin-proteasome system (UPS) [19]. Furthermore, because
ERS can induce autophagy, this could activate other mechanisms in order to remove unfolded proteins
independently of the UPS.
In the next part of this review, we describe the relevance of the UPR/ERS changes that occur
during liver cold ischemia-reperfusion injury. We focus mainly on aspects that concern strategies of
liver graft conservation using static preservation (organ preservation solutions) or machine perfusion
(perfusate solutions), and we assess their relevance in liver transplantation when complete and reduced
liver grafts are used.
3. Unfolded Protein Response (UPR)/ERS in Liver Graft Preservation: The Importance of
Preventing ATP Breakdown
Cold storage protects organs by slowing their metabolism but also causes damage which
is aggravated during cold conservation in the commercial preservation solutions used [20]. It
is well established that hypothermia is a major cause of primary graft non-function, and new
commercial preservation solutions are being developed in order to overcome this problem [21]. The
introduction of University Wisconsin (UW) solution substantially improved graft preservation and
consequently increased patient survival [22]. UW is the gold standard solution, but a limitation is
that it contains hydroxy-ethyl starch (HES) as oncotic agent, conferring on it a high viscosity [23].
Institut Georges Lopez-1 (IGL-1) solution is a later development characterized by the substitution
of HES by Polyethylenglycol-35 (PEG-35) and the reversal of the ionic K+/Na+ concentration [24].
In addition, other solutions with no oncotic agent have been formulated such as Celsior and
histidine-tryptophan-ketoglutarate (HTK), which are used for liver transplantation [25,26]. Table 1
summarizes the differences between the organ preservation solutions [27–29].
During cold storage, the organ is deprived of oxygen and an energy breakdown occurs which
is characterized by ATP depletion [30]. This provokes ischemic injury, which will be further
aggravated during reperfusion. ATP depletion is responsible for the activation of 26S proteasome
(a well-known ATP-dependent enzyme) and of the UPR. This confirms the importance of preventing
energy breakdown during organ cold storage in which the intracellular and extracellular conditions
interfere with ER function. This interference is associated with the accumulation of unfolded proteins
in the ER, resulting in ERS, which will be further aggravated during reperfusion.
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A recent study of the heart reported that a subset of the 26S proteasome is activated at critically
low ATP concentrations. This activated subset was found to contribute to myocardial injury during
cold ischemia, suggesting that proteasome inhibition during hypothermic organ preservation helps to
prolong myocardial viability [31]. This hypothesis was confirmed by the use of proteasome inhibitors to
prevent cardiac proteasome dysfunction during cold storage and reperfusion in a heart transplantation
model in rats [32]. These investigations suggest that the use of proteasome inhibitors may help to
maintain the physiological ubiquitin-protein conjugate pool during cold storage in organ preservation
solutions, thus prolonging liver graft conservation and preventing subsequent cold IRI.
Table 1. Chemical composition of liver graft preservation solutions.
Solution Components University of WisconsinSolution (UW)
Institute George
Lopez 1 (IGL-1) HTK Custodiol
Electrolytes in mM
K+ 125 25 9
Na+ 30 125 15
Mg2+ 5 5 4
Ca2+ 0 0 0.015
Cl´ 0 0 32
SO42´ 5 5 0
Buffers in mM
Diphosphate 25 25 0
Histidine 0 0 180
Histidine-HCl 0 0 18
Tryptophan 0 0 2
Non-Permeants in mM
Raffinose 30 30 0
Lactobionic Acid 100 100 0
Mannitol 0 0 30
Colloids in g/L
Hydroxyethyl Starch 50 0 0
Polyethylene Glycol-35 0 1 0
Antioxidants in mM
Glutathione 3 3 0
Allopurinol 1 1 0
Metabolic Precusors in mM
Adenosine 5 5 0
Ketoglutarate 0 0 1
pH 7.4 7.4 7.2
Osmolarity in mOsmol/L 320 290 310
Besides this ATP depletion, during cold ischemia other cyto-protective factors such as adenosine
mono phosphate protein kinase (AMPK) are activated as a self-response of the organ to oxygen
deprivation. AMPK is stimulated in response to different stress factors in order to restore cellular
and whole-body energy balance. This enzyme is regulated by competitive binding of AMP and ATP,
through sensing cellular energy condition and, when activated, triggers a compensatory mechanism of
ATP generation at the same time that attenuates ATP-consuming processes [33]. AMPK is degraded by
the UPS and this degradation is blocked by the use of 26S proteasome inhibitors.
With this in mind, the use of preservation solution appears to be a useful tool for modulating some
protective cell signaling pathways in cold preservation conditions that interfere with UPR/ER function
and ERS alterations. This includes protective cell signaling pathways such as AMPK and nitric oxide
generation, which are closely associated with the prevention of hepatic cold IRI. In this sense, we have
recently reported that the inhibition of AMPK induced an increase in ERS and a significant attenuation
in autophagy. These data confirm the close relationship between AMPK activation and ER stress and
autophagy after cold IRI [34].
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3.1. UPR/ERS in Liver Graft Cold Storage
Recently data from the European Liver Transplant Registry [35] suggested that UW, IGL-1 and
Celsior solutions are the best alternative for use in liver transplantation and are superior to HTK.
The presence of the oncotic agents HES (in UW) and PEG-35 (in IGL-1) characterize UW and IGL-1
solutions, while HTK and Celsior do not contain oncotic agents (see Table 1).
IGL-1 solution prevents ATP depletion more efficiently than UW after 24 h cold storage and
consequently the activation of UPR is lower than when using UW [36]. Similarly, IGL-1 obtained a
more significant AMPK activation than UW, attributed, in part, to the substitution of HES by PEG-35.
Taking this into account and in view of the benefits of proteasome inhibition in hypothermic heart
preservation [31], we recently explored the use of proteasome inhibitor as additives in UW and IGL-1
solutions for the purposes of liver preservation and transplantation [37]. As it is known that liver
proteolysis during cold storage influences graft outcome after transplantation [38], the supplementation
of UW and IGL-1 solutions with proteasome inhibitors such as MG132 and bortezomib (BZ) at low,
non-toxic doses protected steatotic liver grafts against cold IRI. The inhibition of UPS activity was more
effective with BZ (reversible drug action) than with MG132 (irreversible drug action) when livers were
preserved in UW solution. These benefits were increased when BZ was used as an additive in IGL-1
solution, associating this solution as more effective in the prevention of proteolysis. In this case, the
protective mechanisms were independent of those observed for UW. In the case of BZ, e-NOS activation
promotes NO generation, which contributes to counterbalancing the exacerbated microcirculation
alterations that occur in fatty livers after graft revascularization and transplantation. These findings
corroborate the previous publications by Majetschak et al. in heart [39] confirming that the use of
proteasome inhibitors may contribute to maintain the physiological ubiquitin-protein conjugate pool
in liver grafts during cold storage, thus prolonging their preservation.
In another study, we analyzed the role of melatonin and trimetazidine combination as additives to
IGL-1 solution in the modulation of ERS and autophagy in fatty liver grafts [34]. Both additives showed
a protective effect by reducing ERS markers GRP78, phosphorylated PERK, and C/EBP homologous
protein (CHOP) activation after reperfusion in accordance with an enhanced induction of autophagic
parameters (beclin-1, ATG7, and LC3B) and AMPK phosphorylation.
3.2. UPR/ERS in Liver Graft Machine Perfusion
Simple cold storage and machine perfusion (MP) are the two current strategies to preservation
before transplantation. Simple cold storage’s simplicity, low cost, and need for transport make it
preferential at the majority of transplant centers. Nevertheless, MP includes a range of promising
techniques of liver graft preservation that is currently making the transition into clinical practice.
Recently, it has been reported that the use of MP increases graft function and survival at one year
compared to conventional hypothermic preservation [40]. However, when investigating the impact
of MP with different preservation solutions on ERS of liver grafts from non-heart beating donor rats,
Minor, et al. found that prolonged MP (more than 18 h) induced ERS-associated gene responses [41].
In this context, the occurrence of ERS responses after prolonged hypothermic MP might be lied
to MP-dependence on the preservation solution used when HTK (a substrate free, low viscosity,
extra-cellular type medium) was compared to MP Belzer-MPS (a nutritive, high viscosity, colloidal
intra-cellular type solution), the most used in MP. It is important to remark that the differences could
be associated to the presence of oncotic support on their compositions. HTK does not contain oncotic
agent when compared to MP-Belzer.
With this in mind, the use of reversible UPS inhibitors as additives to Belzer-MPS gluconate
solution or its generics at low, non-toxic concentrations could be useful for normothermic MP. In any
case, a final short perfusion with Belzer-MPS alone may be envisaged in order to eliminate BZ molecule
(reversible UPS inhibitor) traces. The fact that BZ promotes NO generation and AMPK activation, and
also contributes to up regulates liver antioxidative enzymes [42] suggests that this practice might also
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help to reduce the fat in steatotic livers (those with more than 60% steatosis) and recuperate them for
the organ pool.
4. UPR/ERS in Liver Transplantation
Liver transplantation has been considered as the best therapeutic treatment for the patients with
end stage liver disease, including advanced liver cirrhosis and acute liver failure. In any case, IRI is
inevitable and contributes to the early liver graft non-function or late dysfunction, limiting successful
outcome after transplantation.
Distinct ERS responses are triggered during human liver transplantation. Samples from ischemic
and reperfused livers, showed a biphasic activation of UPR pathways [42]. The early ischemic
phase initiated the activation of IRE1α which was further increased upon reperfusion. In addition,
ischemic hepatocytes showed lessened PERK and eIF2α phosphorylation being then enhanced during
reperfusion mainly in sinusoidal endothelial cells. On the other hand, ERS has been recently proposed
as a marker for predicting steatotic liver outcome after transplantation [43]. The study suggests that
the ERS pathways, particularly the CHOP-caspase 11-Interleukin1β pathway, are potential targets to
improve steatotic liver allograft function following liver transplantation.
The consequences of UPS/ERS in liver transplantation have been poorly investigated; especially
with regard to the use of different preservation solutions (see Table 1). The compositions of the
solutions used for graft conservation are crucial for preventing ATP breakdown and for promoting a
differential activation of UPR/ERS after liver transplantation. We have reported that IGL-1 solution
prevented ERS more efficiently than UW by reducing the activation of three pathways of the UPR
(IRE1, PERK and ATF6), as well as their effector molecules caspase 12-CHOP, XBP-1, tumor necrosis
factors-associate factor 2 and eukaryotic translation initiation factor 2 [37]. This was associated with a
reduction in liver injury and apoptosis.
The mechanisms by which IGL-1 confers better protection against ERS and maintains cell viability
are directly related to the prevention of ischemic (activation of UPR by ATP during cold storage) and
reperfusion injury (prevention of oxidative stress and ERS), injuries which are exacerbated during
graft revascularization. The presence of PEG-35 in IGL-1 solution appears to be a key to promoting
cyto-protective factors like AMPK and NO. PEG-35 may also potentiate the benefits of UPS inhibitors
and provide an extra protection for the liver graft against cold IRI.
Because of the lack of organs available for transplantation, living donor liver transplantation
(LDLT) has emerged as an alternative to increase the number of transplantable organs. Although IRI
is also inevitable, the ischemia injury is clearly reduced when compared to cadaveric donors but the
grafts may also be non-functional due to the appearance of small-for-size liver syndrome (SFSS) which
compromises the liver outcome after transplantation [44]. In this case, the prevention of IRI is even
more important in order to obtain rapid liver regeneration, to achieve a suitable critical liver mass after
transplantation and to avert SFSS.
5. Proteasome Inhibitors as Therapeutic Targets for Liver Preservation and Transplantation
The proteasome plays a significant role in not only cell protein degradation, but also in the
proteolysis of misfolded proteins in the ER. In this sense, reversible UPS inhibitors appear as
therapeutic targets for liver preservation in static and dynamic conditions and as potential drugs in
liver transplantation. The development of new reversible UPS inhibitors may increase the efficacy of
dynamic preservation in cold or normo-thermic conditions. They may also be used as pretreatment for
liver transplantation, as potential therapeutic especially at a non-toxic single low dose.
As mentioned before, the supplementation of UW and IGL-1 preservation solutions with
proteasome inhibitors such as MG132 and BZ protects steatotic liver grafts against cold IRI being BZ
more effective than MG132 [37]. The protective effects of this reversible inhibitor have been found to
be partially mediated through the activation of AMPK and Akt/mTOR signaling.
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Regarding the effect of proteasome inhibitors upon experimental liver transplantation, the
pretreatment of rat recipients and donors before reduced-size orthotopic liver transplantation (ROLT)
with BZ and MG123 at single low non-toxic dose have been found to protect small liver grafts [45].
BZ protection is superior to MG132 treatment in ROLT, inducing an overwhelming protection of
mitochondrial damage concomitantly with effective prevention of oxidative stress, ERS and apoptosis,
especially when IGL-1 was used instead of UW [37]. In terms of hepatic regeneration, BZ also
performed better than MG132 and promoted a better hepatocyte proliferation [45].
Another mechanism of action of BZ has been found in transplanted steatotic grafts. Pretreatment
with BZ resulted in significant decrease in NF-κB activation, leading to the reduction of the levels of
pro-inflammatory cytokines [46].
Apart from BZ and MG132, other proteasome inhibitors such as lactacystin and epoxomicin, have
been used to limit IRI in different organs [31,47–49]. Both of these compounds inhibit proteasome
activity, and, additionally epoxomicin prevents the activity of the immunoproteasome, the key complex
in the inflammatory response [50,51]. However, these compounds are not highly specific to proteasome
and are irreversible inhibitors that exert more damage than protecting effects than those obtained with
BZ treatment. The dose of BZ used in our study was within the ranges of the approved therapeutic
concentration in clinical trials for the treatment of multiple myeloma and mantle cell lymphoma. The
potential benefits of UPS inhibitors for limiting liver cold IRI are summarized in Figure 1.
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Figure 1. New perspectives to use ubiquitin-proteasome system (UPS) inhibitors as additives in static
(University Wisconsin (UW) and Institut Georges Lopez-1 (IGL-1) solutions) and dynamic machine
perfusion (MP) (MP Belzer solution) liver preservation; as well as in liver transplantation using
complete (OLT) and reduced grafts (ROLT). In all cases, the protection mechanisms are associated with
the UPS inhibition, mitochondrial protection and activation of pro-survival factors (Akt, adenosine
mono phosphate protein kinase (AMPK)). ROLT, reduced-size orthotopic liver transplantation.
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6. Other Therapeutic Targets for Liver Preservation and Transplantation
The maximum concentrations of calcium within the cell are found in the ER due to the active
transport by Ca2+-ATPases in this organelle. Therefore, derangements of calcium regulation in the
ER also contribute to the problems related with protein unfolding because of the calcium-dependent
nature of some chaperones such as GRP78 and calreticulin 3 [52]. In case of severe and sustained
ERS, calcium release from the ER via IP3 receptors can activate calpains, a family of Ca2+-dependent
cysteine proteases, implicated in the subsequent cell death through different substrates including Bax
and Bid, Bcl-2 and Bcl-xL and several caspases. In this case, the blockade of calpain activation could
be an interesting approach to decrease, at least, cell apoptosis after grafting organs such as liver. In
experimental models of cardiac ischemia/reperfusion, the inhibition of calpain both at pharmacologic
and genetic level have been already demonstrated to ameliorate the ischemic cardiac injury and
improve myocardial function [53–55]. This cell death calcium-dependent can be amplified by the
decrease of cellular ATP. Indeed, low ATP levels during ERS impair the storage of Ca2+ in ER and it is
transported out of the cells [56].
Another source of Ca2+ release from the ER with the potency to ameliorate ERS is via ryanodine
receptor, a calcium-release channel that controls the delivery of Ca2+ into the cytoplasm [57]. In
this sense, the use of the ryanodine receptor antagonist Dantrolene in mice protected the ischemic
liver through the modulation of inflammatory related cytokines Tumor Necrosis Factor alpha and
Interleukin 10 [58].
7. Conclusions
In summary, the involvement of UPR/ERS in solid organ transplantation is probably
underestimated. Modulation of these processes is crucial for preventing the cold IRI associated
with liver transplantation when using either complete or reduced grafts. The use and development of
proteasome inhibitors for future therapeutic applications in clinical transplantation need to be explored
further, placing special emphasis on their potential use as additives in static preservation and MP
solutions. UPS inhibitors and other compounds with potency to ameliorate ERS may also be a useful
tool for recovering some of the fatty livers for transplantation, which are currently discarded, thus
increasing the number of transplantable organs for patients on waiting lists.
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Abbreviations
The following abbreviations are used in this manuscript:
ER endoplasmic reticulum
ERS endoplasmic reticulum stress
UPR unfolded protein response
IRI ischemia-reperfusion injury
UPS ubiquitin proteasome system
ATF6 activated transcription factor 6
IRE1 Requiring enzyme inositol 1
PERK RNA protein kinase (PKR) -like ER kinase
GRP78 78 kDa glucose-regulated protein
BiP immunoglobulin-binding protein
AMPK adenosine mono phosphate protein kinase
HIF1 alpha hypoxia inducible factor 1 alpha
XBP-1 X box binding protein 1
ERAD Endoplasmic reticulum associated protein degradation
eIF2a elongation initiation factor 2a
ATF4 activating transcription factor 4
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UW University of Wisconsin solution
IGL-1 Institut Georges Lopez-1
PEG-35 Polyethylenglycol-35
HTK histidine-tryptophan-ketoglutarate
BZ Bortezomib
CHOP C/EBP homologous protein
Belzer-MPS Belzer gluconate solution
MP Machine perfusion
LDLT Living donor liver transplantation
ROLT reduced-size orthotopic liver transplantation
SFSS Small-for-size liver syndrome
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